Skip to main content
. 2016 Nov 30;8(2):3274–3288. doi: 10.18632/oncotarget.13712

Figure 6. Serum Ab are not able to trigger CDC toward tumor cells.

Figure 6

A-D. Viability of CLL cells incubated for 1 hour with different concentrations of CLL serum, in the presence or in the absence of alemtuzumab. Cell viability was determined by Ann-V/PI staining and cytofluorimetric analysis on CLL cells purified from patients’ samples. A, B. Representative analyses of AnnV/PI expression on CLL cells left untreated or incubated with patient's serum at 25% (A) and 100% (B) concentration, in the presence or in the absence of alemtuzumab. Indicated is the percentage of AnnV/PI double negative (AnnV-/PI-) cells. C, D. Percentage of AnnV-/PI- viable CLL cells. Line plots show that cell viability was significantly reduced when CLL cells were exposed to alemtuzumab (p<0.01). By contrast, there was no significant decrease in cell viability when CLL cells were exposed to sera alone, both at the 25% (C) and 100% (D) concentrations. E-G. CDC assay on the U937 cell line. E. ENO1 surface expression. Representative analyses of ENO1 expression on U937 cells. F. Representative analyses of AnnV/PI expression on U937 cells left untreated or incubated with ENO1-Ab+ patients’ sera at 100% concentration. Indicated is the percentage of AnnV-/PI- cells. G. Percentage of viable AnnV-/PI- U937 cells. Line plot shows no significant decrease in cell viability after exposure of U937 cells to 6 ENO1-Ab+ sera from CLL patients.